Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.

Royer, B; Yin, W; Pegram, M; Ibrahim, N; Villanueva, C; Mir, D; Erlandsson, F; Pivot, X

Royer, B; Yin, W; Pegram, M; Ibrahim, N; Villanueva, C; Mir, D; Erlandsson, F; Pivot, X.

Affiliation

Royer B; CHU Besançon, Laboratoire de Pharmacologie Clinique, Hôpital Jean Minjoz, Besançon, France. broyer@chu-besancon.fr

Br J Cancer ; 102(5): 827-32, 2010 Mar 02.

Article in En | MEDLINE | ID: mdl-20160731

Subject(s)

Antibodies, Monoclonal/pharmacokinetics; Breast Neoplasms/metabolism; Glycolipids/immunology; Glycoproteins/immunology; Adult; Aged; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase I as Topic; Female; Humans; Lipid Droplets; Middle Aged; Models, Biological; Prognosis; Sampling Studies; Survival Rate; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Glycolipids / Glycoproteins / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Br J Cancer Year: 2010 Document type: Article Affiliation country: France Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google